• Capmont sold its minority stake in portfolio company ITM Isotope Technologies Munich as part of ITM’s merger with Telix Pharmaceuticals.
• Telix to acquire 100% of ITM for USD 1.65 billion upfront on a cash- and debt-free basis.
• Deal includes up to USD 700 million in milestone payments tied to regulatory and sales targets for ITM-11.
• ITM shareholders expected to hold about 23.7% of Telix upon completion.
• Closing targeted by the end of Telix’s FY2026, subject to shareholder vote, regulatory clearances, other customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capmont GmbH published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.